News from Bayer
May 16, 2024
Not intended for UK Media – Late-breaking data from pivotal Phase III studies OASIS 1 and 2 to be presented at 2024 ACOG Annual Meeting:
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause
May 15, 2024
Not intended for U.S. and UK Media
Bayer starts Phase I study with novel targeted radionuclide therapy 225Ac-PSMA-Trillium in advanced metastatic prostate cancer
May 14, 2024
Bayer Group:
First-quarter performance as expected